Zyn US shipment volume in Q1 2026
Short Answer
Both the model and the market expect Zyn US shipment volume to be above 185 million in Q1 2026, with no compelling evidence of mispricing.
1. Executive Verdict
- PMI significantly expanded Zyn U.S. production capacity, including new plant.
- FDA authorized 20 ZYN nicotine pouch products for U.S. marketing.
- PMI projects 15-20% Zyn U.S. shipment growth year-over-year for 2026.
- PMI prioritizes Zyn supply for robust U.S. market demand and growth.
- Oral nicotine pouch use significantly increased, especially among younger demographics.
- Velo notably increased its U.S. nicotine pouch market share.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| above 200 million | 15.0% | 18.7% | Model higher by 3.7pp |
| above 215 million | 6.0% | 8.0% | Model higher by 2.0pp |
| above 225 million | 3.0% | 5.5% | Model higher by 2.5pp |
| above 205 million | 11.0% | 14.1% | Model higher by 3.1pp |
| above 210 million | 7.0% | 9.2% | Model higher by 2.2pp |
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This prediction market is newly established and has not yet developed a trading history. The price has remained static at its opening level of 60.0%, indicating a flat or sideways trend. With only a single data point recorded, there have been no price movements, spikes, or drops to analyze. Consequently, it is not possible to correlate price action with any external news or developments. The market's stability is a result of inactivity rather than a consensus reached through active trading.
The total trading volume of 200 contracts was likely executed at the market's inception, establishing the initial 60.0% price. This volume shows some initial interest, but without subsequent trading, it is difficult to assess market conviction or identify any volume patterns. Because the price has not moved from its starting point, no support or resistance levels have been formed. The 60.0% mark is the only significant price point, representing the market's opening assessment.
Overall, the chart reflects a nascent market. The initial sentiment places the probability of the event occurring at 60.0%. However, this sentiment is untested and has not been challenged or confirmed by further trading activity. The lack of price discovery means the current price reflects only the opinion of the earliest participants.
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
Outcome: above 195 million
📉 April 17, 2026: 17.0pp drop
Price decreased from 50.0% to 33.0%
What happened: No supporting research available for this anomaly.
📉 April 16, 2026: 10.0pp drop
Price decreased from 60.0% to 50.0%
What happened: No supporting research available for this anomaly.
📈 April 15, 2026: 16.0pp spike
Price increased from 44.0% to 60.0%
What happened: No supporting research available for this anomaly.
Outcome: above 205 million
📉 April 14, 2026: 19.0pp drop
Price decreased from 41.0% to 22.0%
What happened: No supporting research available for this anomaly.
Outcome: above 200 million
📉 April 13, 2026: 58.0pp drop
Price decreased from 87.0% to 29.0%
What happened: No supporting research available for this anomaly.
4. Market Data
Contract Snapshot
The market resolves to YES if Philip Morris International Inc. reports Zyn US shipment volume above 185,000,000 in Q1 2026, with the outcome verified by Fiscal.ai; otherwise, it resolves to NO. Trading for this market began on April 17, 2026, at 12:30 pm EDT. The market will close early if the event occurs, or by May 22, 2026, at 6:00 am EDT, with projected payouts 30 minutes after closing.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| above 185 million | $0.56 | $0.53 | 56% |
| above 190 million | $0.40 | $0.69 | 41% |
| above 195 million | $0.31 | $0.76 | 32% |
| above 200 million | $0.16 | $0.85 | 15% |
| above 205 million | $0.12 | $0.89 | 11% |
| above 210 million | $0.08 | $0.93 | 7% |
| above 215 million | $0.07 | $0.94 | 6% |
| above 220 million | $0.05 | $0.96 | 6% |
| above 230 million | $0.03 | $0.99 | 6% |
| above 225 million | $0.03 | $0.98 | 3% |
| above 235 million | $0.02 | $1.00 | 1% |
| above 190 million | $0.00 | $1.00 | 0% |
Market Discussion
Traders are generally optimistic about Zyn US shipment volume in Q1 2026, with a 56% chance predicted for volumes above 185 million. Many individual participants are betting "Yes" on even higher thresholds, specifically above 200 million and 205 million, citing strong "supply...demand." While there's bullish sentiment among posters, the probability for shipments above 195 million has significantly dropped by 30 points, suggesting some caution at the highest predicted volumes.
5. What is PMI's Zyn U.S. Production Capacity by Q1 2026?
| Kentucky Facility Expansion Operational | Second half of 2025 [^] |
|---|---|
| Colorado Zyn Facility Official Opening | February 2026 [^] |
| Colorado Facility Production Capacity Target | 300 million cans annually by end of 2026 [^] |
Philip Morris International (PMI) is significantly expanding Zyn production with a new Colorado plant. The company has invested $600 million in a new Zyn production facility in Aurora, Colorado, which officially opened in February 2026 [^]. This facility is designed to achieve an initial annualized production capacity of 300 million cans by the end of 2026, with long-term plans to scale up to 700 million cans annually by 2028 [^].
Key operational expansions confirm increased capacity by early 2026. PMI is investing an additional $232 million in its existing Owensboro, Kentucky, facility, with the expansion projected to be fully operational by the second half of 2025 [^]. This particular milestone indicates a substantial increase in operational capacity that would be active at the start of Q1 2026. Furthermore, the Colorado plant had already commenced producing Zyn pouches in limited quantities during its construction phase, preceding its official opening in February 2026 [^].
A precise total Zyn capacity for Q1 2026 remains unspecified. While the research outlines the new Colorado plant's capacity targets for the end of 2026 and subsequent years, and confirms the operational timeline for the Kentucky expansion by H2 2025, a precise aggregated figure for the total annualized Zyn production capacity across all U.S. facilities specifically at the start of Q1 2026 is not provided in the available materials.
6. How Have Zyn's Competitors Impacted Nicotine Pouch Market Share?
| Velo U.S. Market Share | 10% [^] |
|---|---|
| Zyn U.S. Market Share | 55% [^] |
| Altria 'On!' Brand Performance | Steady growth [^] |
Velo has notably increased its U.S. nicotine pouch market share. This primary competitor to Zyn saw its market share rise from 7.9% to 10% [^]. Concurrently, Zyn's market share decreased to 55%, and its overall growth rate experienced a notable slowdown [^]. These shifts indicate a strengthening competitive environment within the nicotine pouch sector.
Altria's 'On!' also demonstrates steady growth and market influence. This key brand has shown consistent expansion within the nicotine pouch segment and has been called a "game changer" [^]. The brand strengthens Altria's position in the broader oral tobacco market, where nicotine pouches now comprise 55.7% of the total market [^]. While specific quarter-over-quarter data through Q4 2025 is not detailed, the general trends underscore increasing competition and diversification among nicotine pouch brands.
7. Has FDA Restricted Sales of ZYN Flavored Nicotine Pouches?
| FDA Authorization Date | January 13, 2025 [^] |
|---|---|
| Authorized ZYN Products | 20 nicotine pouch products [^] |
| Sales Restriction Status (End of 2025) | No definitive rulings or proposed rulemakings [^] |
The FDA's CTP authorized 20 ZYN nicotine pouch products for marketing. On January 13, 2025, the U.S. Food and Drug Administration's Center for Tobacco Products (CTP) authorized the marketing of 20 ZYN nicotine pouch products following an extensive scientific review of their Premarket Tobacco Product Applications (PMTAs) [^]. This authorization includes popular flavors such as Citrus, Cool Mint, Peppermint, Spearmint, Wintergreen, Menthol, and Cinnamon, indicating these products met the FDA's rigorous standards for market entry [^].
No FDA rulemakings restrict ZYN's popular flavors by 2025. Contrary to the premise of sales restrictions, the FDA's actions by the end of 2025 have been to authorize the marketing of these flavored oral nicotine pouches [^]. The available research does not indicate any definitive rulings or proposed rulemakings issued by the FDA CTP by the end of 2025 that would restrict the sales of ZYN's most popular flavors [^]. These marketing orders permit the continued sale of these products unless the FDA were to withdraw them [^].
8. How is Oral Nicotine Pouch Use Growing Among Young Adults?
| Nicotine Pouch Use Trend | Surge and sharp increase among youth and young adults [^] |
|---|---|
| Key Demographic | Youth and young adults, including 18-34 age group [^] |
| Q1-Q3 2025 Data Availability | Reports covering sales data and market trends available [^] |
Oral nicotine pouch penetration has significantly increased, particularly among younger demographics. Web research indicates a substantial rise in oral nicotine pouch use, specifically within the 18-34 age group. Reports highlight a "surge" in nicotine pouch use among young people [^] and a "sharp increase" among teens [^]. Further studies examining awareness and use of oral nicotine pouches between 2022 and 2024 also confirm a growing prevalence in youth and young adult populations [^].
Specific growth rates and evidence of deceleration are not directly available from source titles. While precise quantitative data on growth rates or signs of market saturation for the first three quarters of 2025 could not be directly extracted from the available source titles, relevant reports are identified. These include a "Nicotine Pouch Sales Data Brief" updated to August 10, 2025, and a "Nicotine Pouch Market Report Q3 2025" [^]. Such documents are expected to contain detailed information on sales volumes, market trends, growth rates, and potential indicators of deceleration or saturation within the specified timeframe.
9. Will Zyn U.S. Supply Be Capped for Global Growth?
| 2026 U.S. Shipment Growth | approximately 15-20% year-over-year [^] |
|---|---|
| Total Zyn Capacity Increase by mid-2026 | approximately 25% [^] |
| Planned International Markets (Initial) | 3-5 priority markets [^] |
Philip Morris International's stated priority for Zyn supply allocation focuses on robust existing demand and continued growth in the U.S. market, concurrently allocating incremental capacity for strategic international expansion [^]. There is no guidance suggesting a potential cap on U.S. shipments; instead, the company is significantly expanding its total manufacturing capacity to support both domestic and global objectives [^]. PMI's strategy emphasizes maximizing Zyn's global potential while firmly anchoring its supply strategy on the established U.S. market, which it identifies as the largest and most profitable [^].
International expansion for Zyn will commence in 3-5 markets in 2026. PMI plans initial, controlled launches in these priority international markets, with entries projected to begin in 2026 [^]. A portion of the incremental manufacturing capacity will support these international allocations. The company is carefully planning these deployments to avoid significant disruption to the U.S. supply, underscoring its commitment to meeting existing U.S. demand [^].
Significant manufacturing expansion supports Zyn's future growth. PMI anticipates a substantial increase in total Zyn production capacity, estimated at approximately 25% by mid-2026 [^]. For 2026, Zyn U.S. shipment volumes are projected to grow by approximately 15-20% year-over-year, supported by continued demand and expanded production capabilities [^]. Management has clarified that while U.S. Zyn shipment volumes are expected to continue growing strongly, this growth will occur at a more measured pace than the explosive expansion seen in 2025, as production fully catches up with demand [^].
10. What Could Change the Odds
Key Catalysts
Catalyst analysis unavailable.
Key Dates & Catalysts
- Expiration: May 22, 2026
- Closes: May 22, 2026
11. Decision-Flipping Events
- Trigger: Catalyst analysis unavailable.
13. Historical Resolutions
No historical resolution data available for this series.
Get Real-Time Research Updates
Sign up for early access to live reports, historical data, and AI-powered market insights delivered to your inbox.
